Scancell Agreement with Major International Biotechnology Company

>> DOWNLOAD LINK 🎞️ #1 <<

>> DOWNLOAD LINK 🎞️ #2 <<

>> COPY / PASTE LINK PLEASE 🎵 MP3 <<

>> YOUR LINK HERE: ___ http://youtube.com/watch?v=U5C5Kea0Xuw

We are very pleased to announce this agreement today with a leading international biotechnology company. This is now the second anti-glycan monoclonal antibody generated via our proprietary GlyMab® platform to be evaluated, the first now being developed under a commercial licence agreement. This provides further validation of the potential of our antibody platform to create novel, differentiated antibody products. Whilst the agreement is for an initial exclusive evaluation period, there is an option to licence, and we look forward to providing the market with any updates in due course. • Professor Lindy Durrant, CEO, Scancell Holdings • • Connect with us on social media • https://x.com/_focusIR_ •   / 94140397   • #SCLP #Biotech

#############################